SynthesisPeerJ2026
Prognostic significance of the CRP-albumin-lymphocyte (CALLY) index in esophageal cancer: systematic review and meta-analysis.
Synthesis in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Esophageal cancer (EC) is associated with marked regional disparities, poor 5-year survival (15%-25%), and limited progress in therapeutic outcomes. The tumor, node, and metastasis (TNM) staging system has reduced accuracy for long-term survival prediction, particularly after neoadjuvant therapy. The C-reactive protein-albumin-lymphocyte (CALLY) index-integrating inflammation (C-reactive protein), nutrition (albumin), and immunity (lymphocytes)-emerges as a novel prognostic biomarker. This study aims to evaluate its association with survival outcomes in patients with EC. Methods: Following the PRISMA guidelines and PROSPERO registration (CRD420251125031), two researchers independently screened and extracted data from all relevant original articles published from database inception to July 2025. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) score. Meta-analysis was performed using RevMan 5.3 software, and the risk of bias was assessed using risk of bias plots and funnel plots. Results: Seven studies involving 2,243 patients were included in this meta-analysis. Pooled multivariate analyses of the included studies demonstrated that the CALLY index was independently associated with 5-year overall survival (OS) and recurrence-free survival (RFS), with a high CALLY index consistently predicting favorable outcomes. Moreover, patients with EC in the high CALLY index group had better 5-year OS and RFS than those in the low CALLY index group. Conclusion: The pretreatment CALLY index is a robust prognostic biomarker that is independently associated with improved OS and RFS in patients with EC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.